UBS OCONNOR LLC - CRINETICS PHARMACEUTICALS IN ownership

CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 128 filers reported holding CRINETICS PHARMACEUTICALS IN in Q1 2023. The put-call ratio across all filers is 0.00 and the average weighting 0.4%.

Quarter-by-quarter ownership
UBS OCONNOR LLC ownership history of CRINETICS PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$1,366,665
+35.1%
121,153
+115.8%
0.04%
+9.4%
Q2 2023$1,011,877
+88.5%
56,153
+68.0%
0.03%
+100.0%
Q1 2023$536,741
-100.0%
33,421
-63.1%
0.02%
-52.9%
Q3 2022$1,777,000,000
+9.0%
90,460
+3.4%
0.03%
+41.7%
Q2 2022$1,631,000,00087,4600.02%
Other shareholders
CRINETICS PHARMACEUTICALS IN shareholders Q1 2023
NameSharesValueWeighting ↓
Saturn V Capital Management LP 623,819$11,336,5019.41%
Finepoint Capital LP 822,745$15,0564.87%
Bain Capital Life Sciences Investors, LLC 2,305,558$42,1924.72%
Opaleye Management Inc. 732,000$13,395,6004.66%
5AM Venture Management, LLC 862,286$15,779,8344.24%
SPHERA FUNDS MANAGEMENT LTD. 671,644$12,291,0852.64%
First Light Asset Management, LLC 1,329,313$24,326,4282.26%
BRAIDWELL LP 3,469,674$63,495,0342.13%
BVF INC/IL 2,736,613$50,080,0182.11%
Perceptive Advisors 4,039,276$73,918,7512.08%
View complete list of CRINETICS PHARMACEUTICALS IN shareholders